Turkish
| dc.contributor.author | Gündüz, R | |
| dc.contributor.author | Yildiz, BS | |
| dc.contributor.author | Özdemir, IH | |
| dc.contributor.author | Özen, MB | |
| dc.contributor.author | Çetin, N | |
| dc.contributor.author | Yavuzgil, O | |
| dc.date.accessioned | 2024-07-18T11:55:59Z | |
| dc.date.available | 2024-07-18T11:55:59Z | |
| dc.description.abstract | CUKUROVA UNIV, FAC MEDICINE | |
| dc.identifier.issn | 2602-3040 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/6653 | |
| dc.language.iso | Article | |
| dc.publisher | 2602-3032 | |
| dc.subject | Purpose: The aim of this study was to compare anti-factor Xa assay and tromboelastogram in evaluation of efficacy of enoxaparin in patients with acute coronary syndrome without ST-segment elevation. Materials and Methods: Twenty-five patients with acute coronary syndrome were involved. Two blood samples were taken on admission and 4 hours after the subcutaneous injection of third dose of 1mg/kg enoxaparin to the patients. AntiFXa, tromboelastogram, activated coagulation time were calculated. Results: A non-significant increase in activated coagulation time was observed after the injection of enoxaparin. After injection enoxaparin thromboelastography parameters changed maximum amplitude(MA) increased (MA basal 65.4 +/- 11.9 after 63.4 +/- 7.8), R time increased (from 5 +/- 1.7 to 8.4 +/- 4.6,), K time increased (from 1.89 +/- 1.06 to 2.56 +/- 1.4), angle increased (from 66.34 +/- 5.6 to 57.9 +/- 11.4). AntiFXa increased. (from 0.122 +/- 0.06 to 0.501 +/- 0.359). Conclusion: Tromboelastography method can be used in assessment of efficacy of enoxaparin in patients with acute coronary syndrome without ST-Segment elevation. | |
| dc.title | Turkish | |
| dc.type | MOLECULAR-WEIGHT HEPARIN | |
| dc.type | UNFRACTIONATED HEPARIN | |
| dc.type | THERAPY | |
| dc.type | IMPACT |